Identification of the human liver cytochrome isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid

Drug Metabolism and Disposition

Volumn 28, Issue 12, 2000, Pages 1449-1456

  Zhou, Shufeng ^a   Paxton, James W ^a,c   Tingle, Malcolm D ^a   Kestell, Philip ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; 6 HYDROXYMETHYL 5 METHYLXANTHENONE 4 ACETIC ACID; ALPHA NAPHTHOFLAVONE; ANTINEOPLASTIC AGENT; CHLORZOXAZONE; CIMETIDINE; COMPLEMENTARY DNA; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; FURAFYLLINE; KETOCONAZOLE; QUINIDINE; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MALE; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; FEMALE; HUMANS; HYDROXYLATION; ISOENZYMES; LIVER; MALE; METHYLATION; MICROSOMES, LIVER; MIDDLE AGED; PROTEINS; SUBCELLULAR FRACTIONS; XANTHENES; XANTHONES;

EID: 0033673590     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: Relation to vascular effects
2. Ethoxyresorufin direct photometric assay of a microsomal O-dealkylation which is induced by 3-methylcholanthrene
3. The cytochrome P450 oxidative system
4. A new class of inhibitory cytochrome P450-complexes formed during metabolism: A comparison with amphetamine and SKF 525-A type complexes
5. Recombinant DNA technology as an investigative tool in drug metabolism research
6. Systematic screening for pharmacokinetic interactions during drug development
7. N-hydroxylation of dapsone by multiple enzymes of cytochrome p450: Implications for inhibition of haemotoxicity
8. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
9. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4acetic acid (DMXAA), a novel antivascular agent (Abstract)
10. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil
11. Urinary excretion of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and its metabolites in cancer patients undergoing a Phase I clinical trial (Abstract)
12. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4acetic acid in the mouse, rat and rabbit
13. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline
14. Cleavage of structure proteins during the assembly of the head bacteriophage 14
15. Human cytochrome P4501A2
16. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism
17. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug
18. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
19. The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
20. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone4-acetic acid
21. p-Nitrophenol hydroxylation: A microsomal oxidation which is highly inducible by ethanol
22. Human cytochrome p450 enzymes-A status report summarizing their reactions, substrates, inducers, and inhibitors
23. Potential antitumour agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-gH-xanthenone-4-acetic acids
24. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution
25. Flavincontaining monooxygenase-mediated N-oxidation of the M(1)-muscarinic agonist xanomeline
26. Characterisation of theophylline metabolism by human liver microsomes
27. Integrated cytochrome P450 reaction phenotyping-Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
28. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
29. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals
30. Measurement of protein using bicinchoninic acid
31. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene
32. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2
33. Use of monoclonal antibody probes against rat hepatic cytochrome P-450c and P-450d to detect immunochemical related enzymes in liver microsomes from different species
34. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8acetic acid and analogues in mice
35. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
36. Tolbutamide and phenytoin hydroxylation by cDNA-expressed human liver cytochrome P4502C9
37. In vitro approaches to predicting drug interactions in vivo
38. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver
39. Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection